Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough Concentration

[1]  G. Paintaud,et al.  Therapeutic Drug Monitoring of Biopharmaceuticals May Benefit From Pharmacokinetic and Pharmacokinetic–Pharmacodynamic Modeling , 2017, Therapeutic drug monitoring.

[2]  P. Goupille,et al.  Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Rheumatoid Arthritis , 2017, Therapeutic drug monitoring.

[3]  D. Mould,et al.  A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease , 2017, Inflammatory bowel diseases.

[4]  G. Paintaud,et al.  Brief Report: Relationship Between Serum Infliximab Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis , 2016, Arthritis & rheumatology.

[5]  P. Goupille,et al.  The underlying inflammatory chronic disease influences infliximab pharmacokinetics , 2016, mAbs.

[6]  S. Vermeire,et al.  Pharmacokinetic Modeling and Simulation of Biologicals in Inflammatory Bowel Disease: The Dawning of a New Era for Personalized Treatment. , 2016, Current drug targets.

[7]  G. Paintaud,et al.  A robust estimation of infliximab pharmacokinetic parameters in Crohn’s disease , 2015, European Journal of Clinical Pharmacology.

[8]  K. Van Steen,et al.  Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. , 2015, Gastroenterology.

[9]  E. Louis,et al.  Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn’s Disease , 2015, Clinical Pharmacokinetics.

[10]  M. Dubinsky,et al.  Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies , 2015, Journal of clinical pharmacology.

[11]  L. A. Christensen,et al.  Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn’s Disease Patients Failing Infliximab , 2015, Digestive Diseases and Sciences.

[12]  P. Rutgeerts,et al.  Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD: Evolution in the Definition and Management of Primary Nonresponse , 2015, Inflammatory bowel diseases.

[13]  P. Rutgeerts,et al.  Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. , 2014, Gastroenterology.

[14]  D. Mould,et al.  Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease: A Population Pharmacokinetic Study , 2014, Inflammatory bowel diseases.

[15]  V. Devauchelle-Pensec,et al.  Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. , 2014, British journal of clinical pharmacology.

[16]  F. Alvarez,et al.  Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipients. , 2014, British journal of clinical pharmacology.

[17]  P. Rutgeerts,et al.  Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial , 2014, Gut.

[18]  S. Iyer,et al.  Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[19]  P. V. van Riel,et al.  The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis. , 2013, British journal of clinical pharmacology.

[20]  U. Kopylov,et al.  The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab , 2013, Gut.

[21]  Hiroshi Suzuki,et al.  Bayesian estimation of pharmacokinetic parameters of vancomycin in patients with decreasing renal function. , 2012, Journal of pharmaceutical sciences.

[22]  P. Goupille,et al.  Should anti-TNF-α drug levels and/or anti-drug antibodies be assayed in patients treated for rheumatoid arthritis? , 2012, Joint, bone, spine : revue du rhumatisme.

[23]  Honghui Zhou,et al.  Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. , 2011, Clinical therapeutics.

[24]  A. Bensman,et al.  Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome. , 2010, British journal of clinical pharmacology.

[25]  P. Goupille,et al.  Trough Infliximab Concentrations Predict Efficacy and Sustained Control of Disease Activity in Rheumatoid Arthritis , 2010, Therapeutic Drug Monitoring.

[26]  P. Goupille,et al.  Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis , 2009, Arthritis research & therapy.

[27]  Honghui Zhou,et al.  PHARMACOKINETICS AND DISPOSITION Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis , 2009 .

[28]  M. Dougados,et al.  Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: results from a randomized control study. , 2009, Arthritis and rheumatism.

[29]  G. Paintaud,et al.  An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of Cetuximab , 2009, Therapeutic drug monitoring.

[30]  G. Paintaud,et al.  Infliximab Pharmacokinetics in Inflammatory Bowel Disease Patients , 2008, Therapeutic drug monitoring.

[31]  Honghui Zhou,et al.  Population Pharmacokinetics of Infliximab in Patients With Ankylosing Spondylitis , 2008, Journal of clinical pharmacology.

[32]  M. Silverberg,et al.  Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[33]  P. Goupille,et al.  An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of Infliximab , 2006, Therapeutic drug monitoring.

[34]  F. Nestle,et al.  Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial , 2005, The Lancet.

[35]  B. Dijkmans,et al.  Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis , 2004, Annals of the rheumatic diseases.

[36]  An Carbonez,et al.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.

[37]  E. Keystone,et al.  The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. , 2002, Arthritis and rheumatism.

[38]  F. Breedveld,et al.  Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. , 1998, Arthritis and rheumatism.

[39]  A H Thomson,et al.  Bayesian Parameter Estimation and Population Pharmacokinetics , 1992, Clinical pharmacokinetics.

[40]  L B Sheiner,et al.  Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. , 1982, Journal of pharmaceutical sciences.

[41]  P. Goupille,et al.  Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. , 2012, British journal of clinical pharmacology.

[42]  A. Prémaud,et al.  Tacrolimus Population Pharmacokinetic-Pharmacogenetic Analysis and Bayesian Estimation in Renal Transplant Recipients , 2009, Clinical pharmacokinetics.